Detecting Ovarian Cancer Relapse Early with Home Sampling and Biomarkers
Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Multiplex Protein Biomarker Test - a Pilot Study
This study is testing a simple home method for women who have finished treatment for ovarian cancer to see if a blood test can help catch any relapses early, even if they don't have symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 125 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Uppsala University Hospital Academic / other |
| Drugs / interventions | bevazicumab, chemotherapy |
| Locations | 1 site (Umeå) |
| Trial ID | NCT06445621 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate a plasma protein biomarker panel for early detection of relapse in symptom-free patients who have completed treatment for ovarian cancer. Participants will use a user-friendly, non-invasive capillary home-sampling method to collect samples. The study will include women in the control program after ovarian cancer treatment at Uppsala University Hospital and Norrlands University Hospital in Sweden. The findings will inform a future national randomized trial focused on optimizing follow-up care for ovarian cancer patients.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 and older who are symptom-free and have no evidence of disease after treatment for stage III-IV epithelial ovarian cancer.
Not a fit: Patients with other cancer diagnoses within the last two years or those who do not speak Swedish may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of ovarian cancer relapses, improving treatment outcomes and survival rates for patients.
How similar studies have performed: While there is limited research specifically on this approach, previous studies have shown the potential for biomarker panels to improve early detection of ovarian cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18 years of age * Included in the control program for ovarian/fallopian/primary peritoneal cancer at at Uppsala University Hospital, Uppsala or in Norrlands University Hospital, Umeå, * Within 3 years after completed primary treatment for stage III-IV epithelial ovarian cancer, or after treatment for relapse * No evidence of disease (normal CA 125 and no tumor detected on radiology or clinical examination). Exclusion Criteria: * Other cancer diagnosis within 2 years (except squamous skin cancer or basalioma). * Non-Swedish speaking. * Not able to understand instructions.
Where this trial is running
Umeå
- Norrlands University Hospital — Umeå, Sweden (Recruiting)
Study contacts
- Principal investigator: Karin Stålberg, A/ Professor — Uppsala University Hospital
- Study coordinator: Karin Stålberg, A/ Professor
- Email: karin.stalberg@uu.se
- Phone: +46186111577
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.